Recurrent Pregnancy Loss Medical Services in China

Recurrent Pregnancy Loss (RPL), defined as two or more consecutive clinical pregnancy losses before 20 weeks of gestation, is a complex and emotionally devastating condition affecting individuals and couples seeking to build a family. While historically defined as three or more losses, contemporary guidelines—including those from the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Human Reproduction and Embryology (ESHRE)—recognize that evaluation should begin after two losses due to the significant psychological burden and increased likelihood of an underlying etiology. Pathogenesis is multifactorial and often idiopathic; however, identifiable causes include parental chromosomal abnormalities (e.g., balanced translocations), uterine structural anomalies (e.g., septate uterus, intrauterine adhesions), endocrine disorders (e.g., uncontrolled thyroid disease, luteal phase defect, poorly managed diabetes), autoimmune factors (notably antiphospholipid syndrome), thrombophilias (inherited or acquired), and emerging evidence implicating chronic endometritis, sperm DNA fragmentation, and immunologic dysregulation at the maternal-fetal interface. Epidemiologically, RPL affects approximately 1–2% of couples attempting conception, with prevalence rising to ~5% when including women reporting two losses. Risk factors span genetic (advanced maternal age >35, paternal age >40), anatomical (congenital Müllerian anomalies, fibroids), lifestyle (smoking, excessive caffeine, obesity, substance use), environmental (occupational toxin exposure), and comorbid medical conditions (PCOS, celiac disease, chronic hypertension). Importantly, up to 50–75% of cases remain unexplained after standard evaluation—highlighting the need for individualized, multidisciplinary care in reproductive medicine. The psychosocial impact is profound: patients frequently experience grief, anxiety, depression, marital strain, social isolation, and diminished self-worth. Many report feeling stigmatized or dismissed by healthcare providers, leading to treatment delays and reduced adherence. Quality of life metrics consistently show impairments comparable to those seen in chronic illnesses such as cancer or heart failure—underscoring RPL not merely as a reproductive issue but as a holistic health concern requiring integrated psychological, endocrinologic, immunologic, and surgical expertise. Early referral to specialized reproductive medicine departments enables comprehensive workup—including karyotyping, pelvic imaging (3D ultrasound, hysterosalpingography, hysteroscopy), hormonal profiling, thrombophilia screening, and immune markers—and facilitates timely, evidence-based interventions tailored to each patient’s unique profile.

Recurrent Pregnancy Loss (RPL), defined as two or more clinically documented pregnancy losses prior to 20 weeks’ gestation, affects approximately 1–5% of couples attempting conception. A comprehensive, evidence-based evaluation is essential before initiating treatment, as RPL has heterogeneous etiologies—including parental chromosomal abnormalities (e.g., balanced translocations), uterine anatomic anomalies (e.g., septate uterus), endocrine disorders (e.g., uncontrolled thyroid disease, luteal phase defect, or poorly managed diabetes), autoimmune factors (notably antiphospholipid syndrome [APS]), thrombophilias (inherited or acquired), and emerging contributors such as sperm DNA fragmentation and endometrial immune dysregulation. In up to 50% of cases, no definitive cause is identified—termed unexplained RPL—necessitating individualized, supportive, and empiric management strategies.

Conservative treatment forms the cornerstone of RPL care, particularly in unexplained cases or when no modifiable risk factors are present. This includes preconception counseling emphasizing lifestyle optimization: smoking cessation, alcohol abstinence, caffeine restriction (<200 mg/day), weight normalization (BMI 18.5–24.9 kg/m²), and regular moderate exercise. Psychological support is integral; cognitive-behavioral therapy (CBT) and peer-led support groups significantly reduce anxiety and depression scores, which correlate with improved live birth rates in longitudinal studies. Serial early ultrasound monitoring (transvaginal at 6–7 weeks, then every 1–2 weeks until fetal viability) provides timely reassurance and reduces uncertainty-related distress. Empiric progesterone supplementation (200–400 mg micronized vaginal progesterone daily from ovulation or positive pregnancy test until 12 weeks) is recommended for women with prior unexplained RPL, based on the PRISM and PROMISE trials demonstrating modest but statistically significant improvement in live birth rates (RR 1.08–1.15). Folic acid (400–800 µg/day) and vitamin D repletion (target serum 25(OH)D >30 ng/mL) are universally advised due to their roles in genomic stability and immunomodulation.

Pharmacologic interventions are targeted to specific diagnoses. For APS, low-dose aspirin (75–100 mg/day) initiated preconception plus prophylactic enoxaparin (40 mg SC once daily) from positive pregnancy test until delivery is standard; this regimen reduces miscarriage recurrence by ~70% compared to aspirin alone. Thyroid autoimmunity (elevated TPO antibodies without overt dysfunction) may warrant levothyroxine titration to maintain TSH <2.5 mIU/L, though evidence for live birth benefit remains mixed. In luteal phase insufficiency confirmed by mid-luteal serum progesterone <10 ng/mL or inadequate endometrial biopsy dating, intramuscular or vaginal progesterone is indicated. Metformin is used adjunctively in PCOS-associated RPL with insulin resistance (HOMA-IR ≥2.5), improving endometrial receptivity and reducing early loss. Emerging agents under investigation include intralipid infusions and granulocyte colony-stimulating factor (G-CSF) for presumed endometrial immune dysfunction, though current data are insufficient for routine recommendation outside clinical trials.

Surgical treatment is reserved for structural uterine pathology. Hysteroscopic metroplasty is the gold-standard intervention for a septate uterus—the most common congenital anomaly linked to RPL—with live birth rates increasing from ~40% to >80% post-correction. Adhesiolysis (via hysteroscopic lysis of intrauterine adhesions) restores endometrial surface area and vascularization in Asherman syndrome. Myomectomy is indicated for submucosal or large intramural fibroids (>4 cm) distorting the cavity, preferably performed laparoscopically or via hysteroscopy to minimize uterine scarring. All surgical procedures require postoperative hormonal suppression (e.g., combined oral contraceptives or GnRH agonist for 2–3 months) followed by endometrial assessment (saline infusion sonohysterography or hysteroscopy) prior to conception attempt.

Treatment in China offers distinct advantages rooted in integrated reproductive medicine infrastructure. Major academic centers (e.g., Peking University Third Hospital, Shanghai Jiao Tong University Affiliated Renji Hospital) operate multidisciplinary RPL clinics combining reproductive endocrinology, clinical genetics, immunology, hematology, and psychology—ensuring seamless diagnostic coordination and rapid turnaround for karyotyping, thrombophilia panels, and endometrial immune profiling (e.g., NK cell subsets, uNK density quantification via CD56+ immunohistochemistry). China’s national health system enables cost-effective access to advanced diagnostics: whole-exome sequencing for embryonic aneuploidy analysis, high-resolution hysterosalpingography with 3D reconstruction, and standardized antiphospholipid antibody testing per Sydney criteria. Traditional Chinese Medicine (TCM) is frequently integrated as adjunctive conservative therapy; randomized trials from Guangzhou Medical University demonstrate that acupuncture combined with progesterone improves implantation rates and reduces inflammatory cytokines (IL-6, TNF-α) in RPL patients. Moreover, China’s robust assisted reproductive technology (ART) ecosystem allows timely transition to IVF with preimplantation genetic testing for aneuploidy (PGT-A) or structural rearrangements (PGT-SR) when indicated—reducing time-to-pregnancy and emotional burden.

Post-treatment recovery emphasizes continuity and prevention. Patients are advised to wait 2–3 menstrual cycles after surgical correction or completion of anticoagulation therapy before attempting conception, allowing endometrial healing and hormonal stabilization. Serial monitoring includes first-trimester serial β-hCG (every 48 hours initially), progesterone levels (if supplemented), and transvaginal ultrasound at 6, 8, and 10 weeks to assess embryonic growth and cardiac activity. Postpartum, long-term follow-up addresses cardiovascular risk mitigation (given APS or thrombophilia), thyroid surveillance, and psychosocial resilience building. Couples are counseled that even with optimal management, the cumulative live birth rate after three losses remains ~60–70%; thus, realistic expectations and shared decision-making remain central. Finally, male factor evaluation—including semen analysis, sperm DNA fragmentation testing (SCD assay or TUNEL), and lifestyle counseling—is routinely incorporated, reflecting the growing recognition of paternal contributions to RPL pathogenesis.